REGENXBIO Eyes 2027 Commercial Launch for Duchenne Gene Therapy as Pivotal Trial Wraps Enrollment
REGENXBIO has completed enrollment in its AFFINITY DUCHENNE pivotal trial for RGX-202, a gene therapy candidate for Duchenne Muscular Dystrophy, with top-line data expected in early Q2 2026 and a BLA submission targeting mid-2026. The company is positioning for a 2027 commercial launch backed by $302 million in liquidity and the industry's largest gene therapy bioreactor. Early clinical results show all four pivotal-dose patients exceeded expected functional outcomes with no serious adverse even
ViaNews Editorial Team (Finance)•